Login / Signup

The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre "Real-Life" Cohort Study.

Roberto CaporaliGiulia CataldiMartina GentileAlice DionisiPaola VolpeAnnacarla FinucciLucrezia VerardiClaudia Di MuzioNoemi ItalianoEleonora CellettiMyriam Di PentaIlenia Di ColaAlessandra MarrelliAlessia AlfonsiFrancesco Delle MonacheFrancesco CipolloneMarco GabiniPaola Cipriani
Published in: Rheumatology and therapy (2024)
The "real-life" 6-month effectiveness of guselkumab was shown in patients with PsA, mainly characterised by active long-standing disease, previously treated with bDMARDs, and with comorbidities. Furthermore, a good DRR of guselkumab was estimated in the cumulative 18 months of follow-up and appeared to be not influenced by long disease duration, comorbidities, obesity, and previous bDMARDs.
Keyphrases
  • prostate cancer
  • randomized controlled trial
  • type diabetes
  • insulin resistance
  • systematic review
  • clinical trial
  • weight loss
  • weight gain
  • adipose tissue
  • cross sectional
  • body mass index
  • double blind